Abstract
Recombinant hemagglutinin (HA) from a novel H1N1 influenza strain was produced using an alphavirus replicon expression system. The recombinant HA vaccine was produced more rapidly than traditional vaccines, and was evaluated as a swine vaccine candidate at different doses in a challenge model utilizing the homologous influenza A/California/04/2009 (H1N1) strain. Vaccinated animals showed significantly higher specific antibody response, reduced lung lesions and viral shedding, and higher average daily gain when compared to non-vaccinated control animals. These data demonstrate that the swine vaccine candidate was efficacious at all of the evaluated doses.
Highlights
The recent outbreak of pandemic or novel H1N1 in the global human population highlights the zoonotic potential of influenza viruses
The novel H1N1 HA gene was inserted into the alphavirus replicon platform according to the methods listed previously
Post-vaccination sera were tested for specific antibody response by the homologous hemagglutination inhibition (HI) assay
Summary
The recent outbreak of pandemic or novel H1N1 in the global human population highlights the zoonotic potential of influenza viruses. A more recent study reviewed reported cases of triple-reassortant swine influenza subtype H1 in humans from 2005-February 2009 [3] They found 11 sporadic cases, and all 11 patients recovered after showing clinical influenza symptoms. Nine of these 11 patients had known exposure to pigs, most of which were ill, either at agricultural fairs or at hog farms. These results mirror studies showing increased antibody titers to swine influenza viruses among hog farm workers and family members [4][5]. Novel H1N1 vaccination can reduce clinical disease in pigs, and may reduce transmission among the swine population and decrease the zoonotic potential
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
